Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

NCT05407441 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Atypical Teratoid Rhabdoid Tumor
INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors
SMARCA4-deficient Primary CNS Malignant Tumors
Malignant Rhabdoid Tumor (MRT)
Rhabdoid Tumor of the Kidney (RTK)
Epithelioid Sarcoma
Chordoma

Interventions

DRUG: Tazemetostat
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Susan Chi, MD

Collaborators

[object Object]
[object Object]